Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer

For patients with early stage IB–IIIA non–small-cell lung cancer (NSCLC), adjuvant chemotherapy has been proven to provide a 5% survival benefit at 5